Market Update: Merck & Co Inc (NYSE:MRK) – Merck’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study

[ Business Wire] – Merck , known as MSD outside the United States and Canada, today announced top-line results from the company’s Phase 3 pivotal trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily formulation of ISENTRESS® , known as raltegravir 600 mg , for previously untreated HIV-1 infected adults. Read more on this. Merck & Co. Inc. (MRK) , with a current value of $140.79B, started the session at $50.28. Looking at the stock , its one day range is $50.16 to $50.54 with the price of the stock fluctuating between $45.69 to $61.70 over the last 52 weeks. MRK shares are currently priced at 13.55x this year’s forecasted earnings, which makes them relatively expensive compared to the industry ’s -4.96x forward p/e ratio. The company pays shareholders $1.84 per share in dividend income per year, for a current yield of 3.67%. Consensus earnings for the current quarter by the 16 sell-side analysts covering the stock is an estimate of $0.85 per share, which would be $0.00 worse than the year-ago quarter and a $0.03 sequential increase. In looking at the bigger picture, the full-year EPS estimate of $3.70 would be a $0.11 better when compared to the previous year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $9.47 Billion. If reported, that would be a 0.53% increase over the year-ago quarter. More recently, BofA/Merrill downgraded MRK from Buy to Neutral (Jan 27, 2016). Previously, Berenberg Initiated MRK at to Hold. The average price target for MRK shares by the analysts covering it is $60.95, which is 21.22% above where the stock opened. See more in (NYSE:MRK) Similar Articles: Stock Update: Merck & Co Inc (NYSE:MRK) – Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence Stock Update (NYSE:MRK): Panel recommends Merck & Co continue cholesterol drug study Market Update: Merck & Co Inc (NYSE:MRK) – Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.